Company research
CV Sciences, Inc.
CIK 1510964Updated Oct 27, 2026
SecurityCVSI · OTC · equity
Historical securities (1)
CANV · OTC · equity · closed Jun 8, 2016Name history
CannaVEST Corp. · through Jan 4, 2016Foreclosure Solutions, Inc. · through Nov 30, 2012
CVSI price & chart
Loading TradingView…
OTC:CVSI on TradingView ↗About the company
CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces non-cannabinoid supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that…
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01
4 filing
3 filing
10-Q filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
DEF 14A filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 6,995,000Source | 8,391,000Source | 6,521,000Source | 7,950,000Source | 8,886,000Source | 6,722,000Source | 7,761,000Source | 8,466,000Source | 6,962,000Source | 7,927,000Source | 9,200,000Source | 12,736,000Source |
| Property, Plant and Equipment, NetUSD | 349,000Source | 490,000Source | 319,000Source | 363,000Source | 666,000Source | 329,000Source | 364,000Source | 319,000Source | 344,000Source | 399,000Source | 379,000Source | 575,000Source |
| GoodwillUSD | 1,010,000Source | 815,000Source | 999,000Source | 1,013,000Source | 729,000Source | 1,001,000Source | 988,000Source | 340,000Source | 1,015,000Source | 971,000Source | 342,000Source | 0Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 82,000Source | 103,000Source | 62,000Source | 88,000Source | 106,000Source | 68,000Source | 90,000Source | 73,000Source | 76,000Source | 93,000Source | 78,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | — | — | — | — | — | — | — | — | 611,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 405,000Source | 422,000Source | 348,000Source | 545,000Source | 639,000Source | 391,000Source | 430,000Source | 507,000Source | 402,000Source | 522,000Source | 431,000Source | 766,000Source |
| Inventory, NetUSD | 4,080,000Source | 5,020,000Source | 3,965,000Source | 4,216,000Source | 5,206,000Source | 3,902,000Source | 4,368,000Source | 5,756,000Source | 4,087,000Source | 4,897,000Source | 5,655,000Source | 6,563,000Source |
| Assets, CurrentUSD | 5,097,000Source | 6,748,000Source | 4,879,000Source | 5,942,000Source | 6,732,000Source | 4,995,000Source | 5,963,000Source | 7,351,000Source | 5,133,000Source | 6,243,000Source | 7,938,000Source | 11,130,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 231,000Source | 327,000Source | 300,000Source | 295,000Source | 410,000Source | 393,000Source | 353,000Source | 426,000Source | 366,000Source | 370,000Source | 535,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 410,000Source | 81,000Source | 215,000Source | 472,000Source | 400,000Source | 282,000Source | 257,000Source | 139,000Source | 347,000Source | 94,000Source | 167,000Source | 275,000Source |
| Other Assets, NoncurrentUSD | 47,000Source | 154,000Source | 47,000Source | 72,000Source | 202,000Source | 47,000Source | 99,000Source | 244,000Source | 47,000Source | 127,000Source | 296,000Source | 505,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 5,456,000Source | 6,200,000Source | 4,950,000Source | 6,147,000Source | 6,378,000Source | 5,224,000Source | 5,869,000Source | 6,104,000Source | 5,494,000Source | 6,132,000Source | 6,297,000Source | 13,513,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Common Stock, Value, IssuedUSD | 18,000Source | 18,000Source | 21,000Source | 18,000Source | 18,000Source | 19,000Source | 18,000Source | 16,000Source | 18,000Source | 18,000Source | 16,000Source | 15,000Source |
| Additional Paid in CapitalUSD | 89,207,000Source | 88,409,000Source | 90,881,000Source | 89,083,000Source | 88,291,000Source | 90,029,000Source | 88,951,000Source | 87,556,000Source | 89,330,000Source | 88,773,000Source | 87,464,000Source | 86,897,000Source |
| Retained Earnings (Accumulated Deficit)USD | -87,733,000Source | -86,255,000Source | -89,357,000Source | -87,351,000Source | -85,799,000Source | -88,582,000Source | -87,090,000Source | -85,215,000Source | -87,939,000Source | -86,981,000Source | -84,587,000Source | -87,689,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 47,000Source | 19,000Source | 26,000Source | 53,000Source | -2,000Source | 32,000Source | 13,000Source | 5,000Source | 59,000Source | -15,000Source | 10,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 1,539,000Source | 2,191,000Source | 1,571,000Source | 1,803,000Source | 2,508,000Source | 1,498,000Source | 1,892,000Source | 2,362,000Source | 1,468,000Source | 1,795,000Source | 2,903,000Source | -777,000Source |
| Liabilities and EquityUSD | 6,995,000Source | 8,391,000Source | 6,521,000Source | 7,950,000Source | 8,886,000Source | 6,722,000Source | 7,761,000Source | 8,466,000Source | 6,962,000Source | 7,927,000Source | 9,200,000Source | 12,736,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 4,786,000Source | 6,143,000Source | 4,943,000Source | 5,705,000Source | 6,031,000Source | 5,180,000Source | 5,252,000Source | 5,959,000Source | 5,000,000Source | 6,109,000Source | 6,115,000Source | 13,314,000Source |
| Operating Lease, Liability, CurrentUSD | 247,000Source | 92,000Source | 218,000Source | 239,000Source | 234,000Source | 246,000Source | 140,000Source | 134,000Source | 247,000Source | 83,000Source | 130,000Source | 117,000Source |
| Accounts Payable, CurrentUSD | 1,214,000Source | 1,886,000Source | 1,059,000Source | 1,440,000Source | 2,307,000Source | 1,080,000Source | 1,496,000Source | 2,460,000Source | 1,044,000Source | 1,925,000Source | 2,309,000Source | 2,284,000Source |
| Operating Lease, Liability, NoncurrentUSD | 162,000Source | 0Source | 0Source | 230,000Source | 233,000Source | 37,000Source | 115,000Source | 23,000Source | 100,000Source | 19,000Source | 58,000Source | 188,000Source |
| Deferred Income Tax Liabilities, NetUSD | 4,000Source | 19,000Source | 7,000Source | 4,000Source | 19,000Source | 7,000Source | 4,000Source | 19,000Source | 7,000Source | 4,000Source | 19,000Source | 11,000Source |
| Other Liabilities, NoncurrentUSD | — | 38,000Source | — | — | 95,000Source | — | — | 103,000Source | — | 0Source | 105,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,874,000Source | 3,422,000Source | 2,631,000Source | 3,003,000Source | 3,461,000Source | 2,647,000Source | 2,846,000Source | 3,248,000Source | 2,447,000Source | 3,424,000Source | 3,422,000Source | 9,690,000Source |
| Long-term DebtUSD | — | — | — | — | — | — | — | — | 1,649,000Source | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 451,000Source | — | 18,000Source | 1,023,000Source | — | 72,000Source | 770,000Source | — | 1,262,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 504,000Source | — | 0Source | 208,000Source | — | 0Source | 498,000Source | — | 387,000Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 23,000Source | 82,000Source | 192,000Source | 334,000Source | 235,000Source | 992,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 148,000Source | 118,000Source | 497,000Source | 258,000Source | 218,000Source | 1,009,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -22,000Source | -100,000Source | -124,000Source | 84,000Source | -352,000Source | -1,065,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -174,000Source | -536,000Source | -827,000Source | -803,000Source | -1,042,000Source | -2,061,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 3,000Source | -15,000Source | -14,000Source | -51,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 101,000Source | -81,000Source | -407,000Source | -861,000Source | 2,253,000Source | -1,885,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | 0Source | 10,000Source | 156,000Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -3,000Source | -40,000Source | -109,000Source | -28,000Source | -156,000Source | 0Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 3,000Source | 40,000Source | 109,000Source | 18,000Source | — | 0Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -68,000Source | 480,000Source | 337,000Source | 32,000Source | -1,391,000Source | 1,121,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 31,000Source | 358,000Source | -176,000Source | -863,000Source | 706,000Source | -764,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 381,000Source | 979,000Source | 266,000Source | 886,000Source | 309,000Source | 812,000Source | 278,000Source | 454,000Source | 1,317,000Source | 611,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 2,000Source | 2,000Source | 6,000Source | 8,000Source | 7,000Source | 6,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 8,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 1,000Source | -1,000Source | 3,000Source | -6,000Source | — | — |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 7,000Source | 6,000Source | 24,000Source | 21,000Source | 1,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | 200,000Source | 300,000Source | 200,000Source | 1,000,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -150,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 0Source | 0Source | 0Source | 0Source | 20,000Source | 38,000Source | 38,000Source | — | 0Source | 127,000Source |
| General and Administrative ExpenseUSD | — | — | 710,000Source | 740,000Source | 708,000Source | 836,000Source | 788,000Source | 960,000Source | 3,153,000Source | 3,986,000Source | — | 12,090,000Source |
| GoodwillUSD | — | — | 1,010,000Source | 815,000Source | 999,000Source | 1,013,000Source | 1,001,000Source | 988,000Source | 1,015,000Source | 971,000Source | 342,000Source | 0Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | — | — | — | — | — | — | — | — | 251,000Source | 1,234,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 251,000Source | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 5,000Source | 0Source | 0Source | 7,000Source | 9,000Source | -8,000Source | -6,000Source | -47,000Source |
| InterestExpenseNonoperatingUSD | — | — | 107,000Source | 115,000Source | 1,000Source | 130,000Source | 93,000Source | 151,000Source | 517,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -382,000Source | -456,000Source | -775,000Source | -261,000Source | -643,000Source | -109,000Source | -958,000Source | -2,394,000Source | 3,102,000Source | -8,214,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | -2,394,000Source | 3,102,000Source | -9,134,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 12,397,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -107,000Source | -115,000Source | 469,000Source | 130,000Source | — | -151,000Source | -479,000Source | -212,000Source | -264,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill) | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Induced Conversion of Convertible Debt Expense | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 3,256,000Source | 3,865,000Source | 2,985,000Source | 3,620,000Source | 3,195,000Source | 3,606,000Source | 13,789,000Source | 15,705,000Source | 16,004,000Source | 16,205,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseUSD | — | — | 1,830,000Source | 2,090,000Source | 1,733,000Source | 1,925,000Source | 1,862,000Source | 2,139,000Source | 7,622,000Source | 9,240,000Source | 9,745,000Source | — |
| Operating Income (Loss)USD | — | — | -275,000Source | -341,000Source | -301,000Source | -131,000Source | -318,000Source | 11,000Source | -470,000Source | -2,190,000Source | 3,360,000Source | -6,847,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -107,000Source | -115,000Source | 469,000Source | 130,000Source | — | -151,000Source | -479,000Source | -212,000Source | -264,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -382,000Source | -456,000Source | -770,000Source | -261,000Source | -643,000Source | -102,000Source | -949,000Source | -2,402,000Source | 3,096,000Source | -8,261,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 5,000Source | 0Source | 0Source | 7,000Source | 9,000Source | -8,000Source | -6,000Source | -47,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -382,000Source | -456,000Source | -775,000Source | -261,000Source | -643,000Source | -109,000Source | -958,000Source | -2,394,000Source | 3,102,000Source | -8,214,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | -0.01Source | -0.01Source | 0.02Source | -0.07Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | -0.01Source | -0.01Source | 0.02Source | -0.07Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 184,264,000Source | 182,261,000Source | 205,086,000Source | 184,264,000Source | 186,920,000Source | 184,264,000Source | 184,264,000Source | 175,585,000Source | 153,954,000Source | 138,034,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 184,264,000Source | 182,261,000Source | 205,086,000Source | 184,264,000Source | 186,920,000Source | 184,264,000Source | 184,264,000Source | 175,585,000Source | 153,955,000Source | 138,034,000Source |
| Interest Expense (non-operating)USD | — | — | 107,000Source | 115,000Source | 1,000Source | 130,000Source | 93,000Source | 151,000Source | 517,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 7,000Source | 6,000Source | 24,000Source | 21,000Source | 1,000Source | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 6,000Source | 7,000Source | 8,000Source | 4,000Source |
| General and Administrative ExpenseUSD | — | — | 710,000Source | 740,000Source | 708,000Source | 836,000Source | 788,000Source | 960,000Source | 3,153,000Source | 3,986,000Source | — | 12,090,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | — | — | 1,579,000Source | 1,778,000Source | 1,450,000Source | 1,844,000Source | 1,562,000Source | 1,658,000Source | 6,752,000Source | 7,168,000Source | 7,085,000Source | 5,550,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -582,000Source | -2,141,000Source | 3,114,000Source | — |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 600,000Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | -1,541,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | -2,394,000Source | 3,102,000Source | -9,134,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 12,397,000Source |
| Research and Development ExpenseUSD | — | — | 24,000Source | 29,000Source | 18,000Source | 50,000Source | 18,000Source | 30,000Source | 122,000Source | 118,000Source | 151,000Source | 307,000Source |
| Selling ExpenseUSD | — | — | 691,000Source | 820,000Source | 644,000Source | 718,000Source | 673,000Source | 731,000Source | 2,803,000Source | 3,166,000Source | — | — |
Filing attachments
cvsi-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 cvsi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results San Diego, CA - August 13, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2026. Second Quarter 2026 an…
Read attachment ↗cvsi-ex99_1.htm · 8-K · 2026-05-14
EX-99.1 2 cvsi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results San Diego, CA - May 14, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2026. First Quarter 2026 and Re…
Read attachment ↗cvsi-ex99_1.htm · 8-K · 2026-03-26
EX-99.1 2 cvsi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results San Diego, CA - March 26, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended December 31, 2025. Fiscal 2025, …
Read attachment ↗cvsi-ex99_1.htm · 8-K · 2026-03-10
EX-99.1 6 cvsi-ex99_1.htm EX-99.1 EX-99.1 March 10, 2026 CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in proven, science-backed natural ingredients and products, today announced that it has modified its existing outstanding notes to i…
Read attachment ↗cvsi-ex99_1.htm · 8-K · 2025-11-13
EX-99.1 2 cvsi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter 2025 Financial Results San Diego, CA - November 13, 2025 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended September 30, 2025. Third Quarter 2025 a…
Read attachment ↗cvsi-ex99_1.htm · 8-K · 2025-08-13
EX-99.1 2 cvsi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter 2025 Financial Results San Diego, CA - August 13, 2025 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2025. Second Quarter 2025 and Re…
Read attachment ↗